Pharmaceuticals News and Research

RSS

Space missions affect sleep patterns in astronauts

The most comprehensive study of sleep patterns during spaceflight has just been published and confirms that astronauts suffer considerable sleep deficiency during both pre-mission training and spaceflight.

10 Aug 2014

Alexza Pharmaceuticals announces availability of ADASUVE inhalation powder in Guatemala

Alexza Pharmaceuticals, Inc. today announced that ADASUVE inhalation powder, pre-dispensed (loxapine) is now available in Guatemala. This approval represents the first ADASUVE approval in Latin America for Ferrer and Alexza.

8 Aug 2014

BioSpecifics Technologies initiates CCH Phase 2 clinical trial in patients with lipoma

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX in the EU, announced today that it has injected the first patient in its placebo-controlled Phase 2 clinical trial of CCH for the treatment of lipoma.

8 Aug 2014

Jazz Pharmaceuticals offers $500 million aggregate principal amount of exchangeable senior notes

Jazz Pharmaceuticals plc today announced that Jazz Investments I Limited, its wholly-owned subsidiary, priced its previously announced offering of $500 million aggregate principal amount of exchangeable senior notes due 2021.

8 Aug 2014

Research highlights widespread use of sleeping medication use among astronauts

In an extensive study of sleep monitoring and sleeping pill use in astronauts, researchers from Brigham and Women's Hospital (BWH) Division of Sleep and Circadian Disorders, Harvard Medical School, and the University of Colorado found that astronauts suffer considerable sleep deficiency in the weeks leading up to and during space flight.

8 Aug 2014

Cancer Research UK, CRT and Astellas collaborate to find new drug targets for pancreatic cancer

Cancer Research UK and its commercial arm, Cancer Research Technology (“CRT”), are to join forces with Astellas Pharma Inc. (Tokyo, President & CEO: Yoshihiko Hatanaka, “Astellas”) to find new drug targets in the fight against cancer, with an initial focus on pancreatic cancer.

8 Aug 2014

3SBio enters into exclusive license with DiNonA for development of Leukotuximab

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with DiNonA Inc. for the development, manufacturing and marketing of Leukotuximab, an anti JL-1 antibody for acute leukemia (AL), including acute myelocytic leukemia (AML) and acute lymphoblastic leukemia (ALL), in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and the Middle East (excluding Cyprus, Egypt, Israel and Turkey).

8 Aug 2014

Vitro toxicity testing an alternative to predict adverse health effects of drugs

In vitro toxicity testing is rapidly being adopted in the pharmaceutical, chemical, and cosmetics industries, for example, as an alternative to animal studies to predict adverse health effects of drugs and personal care products and the health consequences of environmental exposures.

8 Aug 2014

New lifesaving product aims at reducing death toll from heroin abuse

A new, lifesaving product aimed at reducing the death toll from heroin abuse — developed by a professor at the University of Kentucky College of Pharmacy — is in its final round of clinical trials and has received Fast Track designation by the Food and Drug Administration.

7 Aug 2014

Idera collaborates with TMA to advance new potential treatment approach for myositis

Idera Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing nucleic acid therapeutics for patients with cancer and rare diseases, and The Myositis Association (TMA), the only nonprofit organization dedicated to solely serving all patients with inflammatory myopathies, today announced a collaboration to advance a new potential treatment approach for polymyositis and dermatomyositis known as Toll-like receptor (TLR) antagonism.

7 Aug 2014

New tool promises to reduce deaths caused by heroin overdose

A new, lifesaving product aimed at reducing the death toll from heroin abuse - developed by a professor at the University of Kentucky College of Pharmacy - is in its final round of clinical trials and has received Fast Track designation by the Food and Drug Administration.

7 Aug 2014

Z Trim launches soluble dietary fiber ingredient, Biofiber Gum

Z Trim Holdings, Inc., an AgriTech company providing value-added, highly functional ingredients to a variety of industries, announced today the commercial launch of a food-grade, soluble dietary fiber ingredient called Biofiber Gum ("BFG").

7 Aug 2014

Celsion announces financial results for second quarter ended 2014

Celsion Corporation, an oncology drug development company, today announced financial results for the second quarter ended June 30, 2014.

7 Aug 2014

Access Pharmaceuticals enters into exclusive license agreement with Norgine

ACCESS PHARMACEUTICALS, INC., an emerging biopharmaceutical company, today announced that it had entered into an exclusive license agreement with Norgine B.V., a leading independent European specialty pharmaceutical company, for the commercialization of MuGard in Europe.

7 Aug 2014

Soligenix demonstrates improved immunogenicity and rapid action of anthrax vaccine, VeloThrax

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today results demonstrating the improved immunogenicity and rapid action of its anthrax vaccine, VeloThrax™.

7 Aug 2014

Auxilium Pharmaceuticals' total revenues decrease 17% to $83 million in Q2 2014

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, today announced financial results for the second quarter ending June 30, 2014. The Company highlighted important corporate, commercial, regulatory and clinical development updates from the quarter.

7 Aug 2014

UCSF study: Acute psychological stress promotes healing in mouse models of different skin irritations

Brief, acute psychological stress promoted healing in mouse models of three different types of skin irritations, in a study led by UC San Francisco researchers.

7 Aug 2014

Novel therapy takes rheumatoid arthritis treatment in mice to a new level

Rheumatoid arthritis is a condition that causes painful inflammation of several joints in the body. The joint capsule becomes swollen, and the disease can also destroy cartilage and bone as it progresses. Rheumatoid arthritis affects 0.5% to 1% of the world's population. Up to this point, doctors have used various drugs to slow or stop the progression of the disease.

7 Aug 2014

UMass Amherst researcher receives grant to uncover molecular mechanisms of skeletal muscle fatigue

Muscle physiologist Edward Debold at the University of Massachusetts Amherst's School of Public Health and Health Sciences recently received a three-year, $198,000 grant from the American Heart Association to support studies to uncover the molecular mechanisms of skeletal muscle fatigue.

7 Aug 2014

Laboratories at TSRI investigate antibodies to fight Ebola virus

Laboratories at The Scripps Research Institute (TSRI) are investigating antibodies to fight Ebola virus, including the three antibodies recently used to treat two American health care workers infected with the Ebola virus.

5 Aug 2014

Pharmaceuticals News and Research

Space missions affect sleep patterns in astronauts

Alexza Pharmaceuticals announces availability of ADASUVE inhalation powder in Guatemala

BioSpecifics Technologies initiates CCH Phase 2 clinical trial in patients with lipoma

Jazz Pharmaceuticals offers $500 million aggregate principal amount of exchangeable senior notes

Research highlights widespread use of sleeping medication use among astronauts

Cancer Research UK, CRT and Astellas collaborate to find new drug targets for pancreatic cancer

3SBio enters into exclusive license with DiNonA for development of Leukotuximab

Vitro toxicity testing an alternative to predict adverse health effects of drugs

New lifesaving product aims at reducing death toll from heroin abuse

Idera collaborates with TMA to advance new potential treatment approach for myositis

New tool promises to reduce deaths caused by heroin overdose

Z Trim launches soluble dietary fiber ingredient, Biofiber Gum

Celsion announces financial results for second quarter ended 2014

Access Pharmaceuticals enters into exclusive license agreement with Norgine

Soligenix demonstrates improved immunogenicity and rapid action of anthrax vaccine, VeloThrax

Auxilium Pharmaceuticals' total revenues decrease 17% to $83 million in Q2 2014

UCSF study: Acute psychological stress promotes healing in mouse models of different skin irritations

Novel therapy takes rheumatoid arthritis treatment in mice to a new level

UMass Amherst researcher receives grant to uncover molecular mechanisms of skeletal muscle fatigue

Laboratories at TSRI investigate antibodies to fight Ebola virus

Event guide: World ADC Asia eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence